Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Agenus Inc (AGEN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Agenus's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
12.760 +1.070    +9.15%
29/04 - Closed. Currency in USD ( Disclaimer )
Pre Market
12.700
-0.060
-0.470%
9:08:45 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 2,800,335
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 11.770 - 14.240
Agenus 12.760 +1.070 +9.15%

Agenus Inc Company Profile

 
Get an in-depth profile of Agenus Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

533

Equity Type

ORD

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Contact Information

Address 3 Forbes Road
Lexington, 02421-7305
United States
Phone 781 674 4400
Fax 781 674 4200

Top Executives

Name Age Since Title
Marcela V. Maus - - Member of Scientific Advisory Board
Garo H. Armen 68 1994 Founder, Executive Chairman & CEO
Manuel Hidalgo 53 - Member of Scientific Advisory Board
Daniel D. Von Hoff - - Member of Scientific Advisory Board
Larry Norton 76 2023 Member of Advisory Board
Timothy R. Wright 65 2006 Independent Lead Director
Brian J. Corvese 65 2007 Independent Director
Robert Benjamin Stein 72 2014 Member of Advisory Board
Ulf Arne Wiinberg 65 2016 Independent Director
Allison M. Jeynes-Ellis 57 2018 Independent Director
Susan B. Hirsch 70 2020 Independent Director
Todd Jude Yancey - 2023 Member of Advisory Board & Chief Strategic Advisor
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

AGEN Comments

Write your thoughts about Agenus Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Chiaretto Calo
Chiaretto Calo Feb 22, 2024 9:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://seekingalpha.com/article/4663512-agenus-2024-may-finally-be-year-major-turnaround
Edward Lee
Fibonacci6180 Jul 10, 2023 9:08PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Trading idea - Entry point has to be over 1.7/61.80%
Jill Fisher
Jill Fisher Jun 05, 2023 10:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Very nice, is it now starting to go up
Jill Fisher
Jill Fisher Apr 10, 2023 11:30AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It looks like finished
László Rádi
László Rádi Mar 30, 2023 8:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
phase1 was fair enough, lets see phase2, it should worth 2.2-2.6$
Jill Fisher
Jill Fisher Mar 10, 2023 10:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why this sell off
mike MIKE
mike MIKE Oct 26, 2022 10:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Agenus has only 260 employees in the US, and recently posted 42 new US job listings. Looks like they are poised for growth. Anyone have additional insight?
Shayne Long
Shayne Long Aug 30, 2021 9:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Ive been in this stock since april. This is the time in biopharma where all the money is made investing. If you buy now, you should see at least a 40% gain before news of approval, or not from FDA in December on Bal 1881 for cervical cancer.
Johnny Soler
Johnny Soler Aug 30, 2021 9:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
looks like the perfect time to buy
Tamr Salem
Tamr Salem Jun 17, 2021 11:25AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good to buy guys?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email